Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

This setup has several favorable features: it is a Phase 2b study rather than an early exploratory readout, uses a randomized double-blind placebo-controlled design, and measures a highly relevant clinical endpoint with 48 weeks of follow-up. Exacerbation rate is a standard efficacy target in moderate-to-severe asthma, so if lunsekimig has real biologic activity, this design should be capable of detecting it. Sanofi’s sponsorship also lowers pure operational risk for a global multicenter trial. The main caution is that the population appears broad moderate-to-severe asthma without any stated biomarker enrichment or subtype restriction. In asthma, placebo-controlled add-on studies can miss when modern background therapy suppresses event rates or when heterogeneity dilutes treatment effect. Dose ranging increases the chance that at least one regimen works, but it also creates room for a messy or nonconvincing dose-response pattern. Because the prompt provides no prior efficacy signal, mechanism detail, or sample-size context, the case for success is only modestly above a coin flip, not a high-conviction positive call.

Lunsekimig is a novel bispecific NANOBODY targeting both TSLP and IL-13, two validated asthma pathways. The Phase 1b proof-of-mechanism study showed a single dose was well tolerated and achieved highly significant FENO reduction (p<0.0001) with robust T2 biomarker suppression and lung function improvements. Both anti-TSLP (tezepelumab) and anti-IL-13 (tralokinumab) monotherapies have individually demonstrated efficacy in asthma, supporting dual targeting. The AIRCULES trial (N=685) is well-powered with 4 dose groups across 48 weeks, using annualized exacerbation rate as a clinically meaningful and regulatorily accepted endpoint. Sanofi's commitment is clear: they expanded lunsekimig into COPD and CRSwNP even before AIRCULES readout, and the trial status is 'Completed.' However, this is a Phase 2b dose-ranging study requiring at least one dose arm to show statistical significance. Base rates for Phase 2 asthma biologics hitting primary endpoints run ~45-55%. The strong biomarker data and validated dual MOA tilt this modestly above 50%, but dose-response uncertainty and the broad unselected population introduce risk. No results have been publicly disclosed as of April 2, 2026.

This is a Phase 2b Sanofi-run dose-ranging study for Lunsekimig in moderate-to-severe asthma with a clinically meaningful primary endpoint (annualized exacerbation rate over 48 weeks). The trial is completed but results are not yet disclosed. Phase 2b studies typically have moderate success rates (40-60%) depending on target validation and prior data. Sanofi has substantial respiratory expertise, suggesting good operational execution. The placebo-controlled parallel-group design is robust. However, asthma is a competitive space with many therapies, and dose-ranging studies carry inherent uncertainty about optimal dosing. Without disclosed Phase 1/2 prior data, intrinsic probability leans modestly positive but remains highly uncertain, placing it slightly above even odds.

This is a well-designed Phase 2b dose-ranging study by Sanofi in moderate-to-severe asthma, targeting a clinically meaningful endpoint of annualized exacerbation rate reduction over 48 weeks. The primary endpoint is objective and standard for asthma trials. The study is already completed, reducing operational and enrollment risks. While dose-ranging studies carry inherent uncertainty in identifying a clear winner, the sponsor's experience and the targeted mechanism provide a basis for cautious optimism. However, Phase 2 success rates in asthma are moderate, and without detailed prior data, confidence is tempered. The primary completion date has passed, so results are imminent, adding to disclosure risk but not trial execution risk.

Phase 2b dose-ranging design is strong: randomized, double-blind, placebo-controlled, parallel-group across SC lunsekimig doses vs placebo, ideal for efficacy signal detection. Primary endpoint (annualized exacerbation rate, baseline to week 48) is high-quality, validated, clinically meaningful, and powered for asthma trials. Patient population (adults 18-80 with moderate-severe asthma) is representative, inclusive, on standard background therapy. Sanofi (SNY) has respiratory expertise (e.g., Dupixent), ensuring solid operational execution in global multicenter setup, low dropout/exclusion risks. No prior data provided, but Ph2b status implies positive Ph1/early signals. Trial completed 38 days past primary (data mature); disclosure risk low as sponsor incentivized for topline soon. Dose-ranging boosts odds of positive (e.g., high-dose superiority). Intrinsic YES ~62% vs historical ~45-50% Ph2 asthma biologics.

This Phase 2b dose-ranging study for lunsekimig in moderate-to-severe asthma has completed, and the probability of a positive outcome is high. Sanofi is advancing this IL-13/IL-4 inhibitor, a validated mechanism in asthma with successful precedents like lebrikizumab and dupilumab. The primary endpoint, annualized rate of asthma exacerbation events over 48 weeks, is a robust and clinically meaningful efficacy measure highly sensitive to anti-inflammatory biologics. The study design includes a broad dose range, which statistically increases the likelihood of identifying at least one effective dose. Furthermore, the large patient population (adults 18-80) enhances statistical power. Given the established mechanism of action and the sponsor's deep expertise in respiratory trials, the risk of operational failure or a flat dose-response is low. The primary completion date has passed, meaning data lock is imminent or complete, eliminating enrollment and execution risks. The primary risk is a narrow therapeutic window, but the dose-ranging design mitigates this by testing multiple exposure levels.

Phase 2b dose-ranging study for moderate-to-severe asthma with annualized exacerbation rate as primary endpoint is a standard, well-validated design. Sanofi has strong respiratory expertise. The trial completed 38 days ago on schedule, suggesting clean execution without safety holds. Lunsekimig is a novel biologic; prior Phase 2a data likely supported progression to this larger study. Placebo-controlled design in symptomatic population with objective exacerbation endpoint reduces placebo response risk. No disclosure of negative results yet 38 days post-completion suggests results may still be under analysis or positive. Typical pharma disclosure lag is 4-8 weeks. The 48-week treatment duration and exacerbation endpoint provide robust signal detection. Moderate-to-severe asthma population has high unmet need and established regulatory path for biologics.

Sanofi's lunsekimig (SAR443765) is a novel bispecific Nanobody targeting both IL-13 and TSLP, two pathways with heavily validated clinical utility in moderate-to-severe asthma. Blockade of these pathways by approved biologics (e.g., dupilumab and tezepelumab) is known to substantially reduce asthma exacerbations. AIRCULES is a Phase 2b dose-ranging study evaluating lunsekimig against placebo in 685 adults with moderate-to-severe asthma over 48 weeks. This large sample size provides tremendous statistical power to detect a significant improvement in the primary endpoint, the annualized rate of asthma exacerbation events versus placebo. Prior Phase 1b proof-of-mechanism data demonstrated that lunsekimig was well-tolerated while significantly suppressing Type 2 inflammation biomarkers (such as FeNO) and improving lung function. Furthermore, Sanofi has already expanded lunsekimig's clinical development into high-risk asthma (the AIRLYMPUS Phase 2 trial), chronic rhinosinusitis, and COPD, and initiated an open-label long-term extension study for AIRCULES participants. This broad pipeline expansion underscores strong internal conviction in the asset's mechanism of action and safety profile. Given the deeply de-risked biological targets, the substantial statistical power from enrolling 685 patients, and the trial design testing against placebo, the probability of technical success is exceptional.

The trial is a Phase 2b study with a randomized, double-blind, placebo-controlled design, which is a robust setup for assessing efficacy. The primary endpoint of annualized rate of asthma exacerbation events is clinically relevant. Given that the study is completed and assuming positive results would likely be reflected in the data, there's a reasonable basis to expect a positive outcome. However, the exact results aren't provided, so some uncertainty remains.